Oncogenex Technologies Inc.
Records under this name other than patents Oncogenex Technologies Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Oncogenex Technologies Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,383,336 | Antisense formulation Lapsed on the fee record Ended Feb 26, 2021 · From the USPTO record | Lapsed on the fee record | Ended Feb 26, 2021 | From the USPTO record |
| US 6,383,808 | Antisense inhibition of clusterin expression Term ended Term ended Sep 11, 2020 · From the USPTO record | Term ended | Term ended Sep 11, 2020 | From the USPTO record |
| US 9,381,209 | Treatment of Squamous Cell Carcinoma with HSP27 Antisense Oligonucleotides and Radiotherapy Formerly held Lapsed on the fee record Ended Jul 5, 2020 · High confidence | Lapsed on the fee record | Ended Jul 5, 2020 | High confidence |
| US 9,326,993 | Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors Lapsed on the fee record Ended May 3, 2020 · From the USPTO record | Lapsed on the fee record | Ended May 3, 2020 | From the USPTO record |
| US 9,200,285 | Clusterin Antisense Therapy for Treatment of Cancer Formerly held Lapsed on the fee record Ended Dec 1, 2019 · Medium confidence | Lapsed on the fee record | Ended Dec 1, 2019 | Medium confidence |
| US 8,987,223 | Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors Lapsed on the fee record Ended Mar 24, 2019 · From the USPTO record | Lapsed on the fee record | Ended Mar 24, 2019 | From the USPTO record |
| US 8,710,020 | Clusterin Antisense Therapy for Treatment of Cancer Formerly held Lapsed on the fee record Ended Apr 29, 2018 · High confidence | Lapsed on the fee record | Ended Apr 29, 2018 | High confidence |